The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Dr Joost van Herten joins Ethics Talk to discuss how comparing different conceptions of health can help us interrogate just exactly what a One Health approach to health offers and what it doesn't.
Dr Rajesh R. Tampi joins Ethics Talk to discuss his article, coauthored with Drs Aarti Gupta and Iqbal Ahmed: “Why Does the US Overly Rely on International Medical Graduates in Its Geriatric Psychiatric Workforce?”
The pace at which neurotechnological developments are being translated into clinical applications calls for a preparatory neuroethical model that can plot the benefits, burdens, and risks of neurosurgery as a step toward minimizing risks and maximizing benefits.